(833) 317-6278
Book a Demo
David Statman
Gray shield icon
Is this you?
Claim your profile.

David Statman

Editorial Features Manager

AS SEEN ON
Healio, TALL PINES HEALTHCARE, INC

Preston's Summary

David Statman is an Editorial Features Manager at Healio. With a background in medical publishing since January 2022, he focuses on themes related to medicine and healthcare, including alternative medicine and medical specialties, while also covering general assignment news and government and politics. Statman has been featured in Healio and TALL PINES HEALTHCARE, INC.

Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston

Geo Focus

Coverage Attributes:

Beta
Cites Data: 61 %
Expert Commentary: 23 %
Press Release: 8 %
Exclusive: 6 %

Themes Covered:

Not enough data icon

Not enough data

Most Recent Topics:

  • Hematology
  • Oncology
  • Pathology
  • Gene Therapy
  • Immunology
  • Surgery

Pitching Insights

David Statman focuses on medical research, particularly in the healthcare and pharmaceutical sectors. His articles are data-driven, often citing specific studies or clinical trials. He would likely be interested in receiving pitches related to new scientific findings, breakthroughs in medical treatments or therapies, and insights from experts involved in these areas.

Given his strong emphasis on citing data and press releases, he is more inclined towards evidence-based information rather than speculative content. Pitches should center around concrete scientific discoveries or developments within the specified medical conditions and treatments mentioned in his article titles.

While there isn't a specified geographic focus for David's coverage, it seems that the topics he covers have global relevance. Therefore, relevant pitches could come from experts or organizations worldwide who can provide valuable insights into these particular areas of medical research.

This information evolves through artificial intelligence and human feedback. Improve this profile .

Journalists With Similar Coverage:

Based on similarity of content.
Helen Albert

Helen Albert

Senior Editor
******t@**********************e.com
Publications
Inside Precision Medicine, BioPharma-Reporter, Outsourcing-Pharma, Genetic Engineering & Biotechnology News
Most recent topics
Not enough data
Holly Liptak

Holly Liptak

Editorial Assistant
******k@********om
Publications
Healio
Most recent topics
Not enough data
Patrick Campbell

Patrick Campbell

Managing Editor
*******ll@***************.com
Publications
HCP Live, JD Supra, Urology Times
Most recent topics
Not enough data
Erin Michael

Erin Michael

Publications
Healio
Most recent topics
Not enough data
Marley V. Ghizzone

Marley V. Ghizzone

Publications
Healio
Most recent topics
Not enough data
Liam Davenport

Liam Davenport

Publications
MDEdge, Medscape, Guidelines Co, The Heights, Inc., Cancer Research Prevention
Most recent topics
Not enough data

Articles

Healio

Leukemia fields ‘moving towards’ menin inhibitors as earlier-line therapy

Leukemia fields ‘moving towards’ menin inhibitors as earlier-line therapy

By: David Statman

In this video, Daniel DeAngelo, MD, PhD, discusses a study presented at ASH Annual Meeting that examined the KOMET-007 study into the use of menin inhibitors in patients with acute myeloid leukemia.DeAngelo, chief of the division of leukemia at Dana-Farber Cancer Institute, highlighted the study, which probed the menin inhibitor ziftomenib [Kura Oncology] combined with intensive therapy.

Healio

Anticoagulant genes may link factor V Leiden, prothrombin mutations and VTE

Anticoagulant genes may link factor V Leiden, prothrombin mutations and VTE

By: David Statman

In this video, Iberia Romina Sosa, MD, PhD, discusses the results of a study presented at ASH Annual Meeting and Exhibition, which examined Factor V Leiden and prothrombin mutation and the risk for venous thromboembolism.Sosa, an associate professor and chief of the division of hematology at Fox Chase Cancer Center, highlighted the study, which identified three specific anticoagulant genes that

Healio

Type I protein S deficiency may be linked to venous thromboembolism

Type I protein S deficiency may be linked to venous thromboembolism

By: David Statman

In this video, Iberia Romina Sosa, MD, PhD, discusses the results of a study presented at ASH Annual Meeting and Exposition, which examined the risk of thrombosis in patients with a protein S deficiency.Sosa, an associate professor and chief of the division of hematology at Fox Chase Cancer Center, highlighted the study, which studied datasets and uncovered indications that specifically type I

Healio

Obinutuzumab useful for refractory thrombotic thrombocytopenic purpura

Obinutuzumab useful for refractory thrombotic thrombocytopenic purpura

By: David Statman

In this video, Iberia Romina Sosa, MD, PhD, discusses the results of a study presented at ASH Annual Meeting and Exposition, which examined the use of obinutuzumab in patients with thrombotic thrombocytopenic purpura.Sosa, an associate professor and chief of the division of hematology at Fox Chase Cancer Center, highlighted the study, which studied the use of obinutuzumab (Gazyva, Genentech) in

© 2025 Intelligent Relations